A number of other equities analysts have also recently issued reports on the company. Lake Street Capital restated a buy rating and set a $12.00 price target on shares of AVITA MED LTD/S in a report on Thursday, March 5th. BTIG Research restated a buy rating and set a $8.00 price target on shares of AVITA MED LTD/S in a report on Thursday, June 18th. Oppenheimer began coverage on AVITA MED LTD/S in a report on Monday, June 15th. They set a buy rating and a $9.00 price target on the stock. Finally, Zacks Investment Research lowered AVITA MED LTD/S from a buy rating to a hold rating in a research report on Tuesday, June 23rd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. AVITA MED LTD/S has a consensus rating of Buy and an average target price of $8.88.
AVITA MED LTD/S stock opened at $30.54 on Friday. The stock has a market capitalization of $560.31 million, a price-to-earnings ratio of -78.31 and a beta of 1.23. AVITA MED LTD/S has a 52-week low of $5.50 and a 52-week high of $55.35. The stock’s 50 day moving average price is $6.19 and its two-hundred day moving average price is $7.40. The company has a debt-to-equity ratio of 0.03, a quick ratio of 15.22 and a current ratio of 15.36.
About AVITA MED LTD/S
Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin.
See Also: How to calculate compound interest
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for AVITA MED LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA MED LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.